Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A phospholipid-like charge-reversible lipid for PEG-free, stable, and low-inflammatory mRNA lipid nanoparticles.

Journal of pharmaceutical sciences·2026

Same author

Biodegradable peptide-based nanoparticles for the in vivo sequestration and neutralization of toxic peptides.

Biomaterials·2026

Same author

Influence of Size, Flexibility, Hydrophobicity, Surface Charge, and Surface Chemistry on the Biodistribution of Orally Administered Polymer Nanoparticles.

Biological & pharmaceutical bulletin·2025

Same author

In vivo delivery of antioxidant enzymes with multi-functionalized lipid nanoparticles for sepsis therapy.

Journal of controlled release : official journal of the Controlled Release Society·2025

Same author

Prediction and control of the particle size of polyethylene glycol-free lipid nanoparticles using a design of experiment.

Biochemical and biophysical research communications·2025

Same author

Process Optimization of Charge-Reversible Lipid Nanoparticles for Cytosolic Protein Delivery Using the Design-of-Experiment Approach.

Biological & pharmaceutical bulletin·2025

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Angiogenic vessel-targeting DDS by liposomalized oligopeptides.

Tomohiro Asai¹, Naoto Oku

¹Department of Medical Biochemistry and Global COE, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

Methods in Molecular Biology (Clifton, N.J.)

|January 15, 2010

Summary

This study developed novel liposomal oligopeptides that target tumor angiogenic vessels. These targeted nanocarriers show promise for improved drug delivery and cancer therapy.

More Related Videos

Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles

Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles

Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

Area of Science:

Nanotechnology
Biomedical Engineering
Oncology

Background:

Liposomal oligopeptides are advanced nanocarriers for targeted drug, DNA, or siRNA delivery.
Tumor angiogenesis presents a key target for cancer therapies.

Purpose of the Study:

To develop liposomal oligopeptides specifically targeting tumor angiogenic vessels.
To evaluate the efficacy of these targeted nanocarriers in preclinical cancer models.

Main Methods:

In vivo biopanning with a phage-displayed peptide library identified the Ala-Pro-Arg-Pro-Gly (APRPG) peptide as a ligand for angiogenic vessels.
Synthesis of a novel lipid derivative (DSPE-PEG-APRPG) for surface modification of PEGylated liposomes.
Evaluation of intratumoral distribution, therapeutic efficacy of encapsulated drugs (adriamycin, DPP-CNDAC), and preparation of modified liposomes.

Main Results:

The APRPG peptide was successfully identified as a specific ligand for angiogenic vessels.
DSPE-PEG-APRPG facilitated the display of peptides on PEGylated liposomes, enabling targeted delivery.
Demonstrated improved intratumoral distribution and therapeutic efficacy of encapsulated anticancer drugs.

Conclusions:

Liposomal oligopeptides modified with APRPG peptide represent a promising strategy for targeted cancer therapy.
This approach enhances drug delivery to tumor angiogenic vessels, potentially improving treatment outcomes.
Further research is warranted to translate these findings into clinical applications.